TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 SEK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
597,542
|
415,292
|
258,386 |
Financial expenses |
46,283
|
55,693
|
20,205 |
Earnings before taxes |
94,521
|
22,314
|
6,665 |
EBITDA |
64,097
|
48,576
|
-7,460 |
Total assets |
2,195,611
|
1,733,084
|
1,542,596 |
Current assets |
826,405
|
467,508
|
547,532 |
Current liabilities |
134,488
|
134,896
|
104,519 |
Equity capital |
1,945,045
|
1,430,136
|
1,285,450 |
- share capital |
805
|
762
|
754 |
Employees (average) |
130
|
114
|
92 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
88.6%
|
82.5%
|
83.3% |
Turnover per employee |
4,596
|
3,643
|
2,809 |
Profit as a percentage of turnover |
15.8%
|
5.4%
|
2.6% |
Return on assets (ROA) |
6.4%
|
4.5%
|
1.7% |
Current ratio |
614.5%
|
346.6%
|
523.9% |
Return on equity (ROE) |
4.9%
|
1.6%
|
0.5% |
Change turnover |
182,250
|
156,906
|
78,525 |
Change turnover % |
44%
|
61%
|
44% |
Chg. No. of employees |
16
|
22
|
29 |
Chg. No. of employees % |
14%
|
24%
|
46% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.